Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor.

Antimicrobial agents and chemotherapy - 1 Jan 1996

Lin P F, Samanta H, Bechtold C M, Deminie C A, Patick A K, Alam M, Riccardi K, Rose R E, White R J, Colonno R J

Abstract excerpt

The human immunodeficiency virus (HIV) fusion inhibitor siamycin I, a 21-residue tricyclic peptide, was identified from a Streptomyces culture by using a cell fusion assay involving cocultivation of HeLa-CD4+ cells and monkey kidney (BSC-1) cells expressing the HIV envelope gp160. Siamycin I is effective against acute HIV type 1 (HIV-1) and HIV-2 infections, with 50% effective doses ranging from 0.05 to 5.7...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to Base Sequence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line

Share to Drug Resistance, Microbial

Share to HeLa Cells

Share to Molecular Sequence Data

Share to Mutation

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 8787894
DOI: 10.1128/AAC.40.1.133
PMCID: PMC163071

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor.PMID 8787894Read ↗

Rapid propagation of low-fitness drug-resistant mutants of human immunodeficiency virus type 1 by a streptococcal metabolite sparsomycin.Semantic proximity Read ↗

In vitro activity of stampidine against primary clinical human immunodeficiency virus isolates.Semantic proximity Read ↗

Novel Therapies Based on Mechanisms of HIV-1 Cell EntrySemantic proximity Read ↗

Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC.Semantic proximity Read ↗

Escape from Human Immunodeficiency Virus Type 1 (HIV-1) Entry InhibitorsSemantic proximity Read ↗

Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.Semantic proximity Read ↗

Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency VirusSemantic proximity Read ↗

Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.